Safety Study of GE-145 320 mg I/mL Injection vs. Iopamidol 370 mg I/mL in Elderly Subjects Undergoing Coronary Procedure

General Electric (GE)

Status and phase

Completed

Phase 2

Conditions

Diabete Mellitus

Chronic Renal Insufficiency

Congestive Heart Failure

Treatments

Drug: GE-145

Study type

Interventional

Funder types

Industry

Identifiers

NCT01252810

GE 145-002

Details and patient eligibility

About

To evaluate cardio-renal and overall safety profile of GE 145 320 mg I/ml Injection when compared to iopamidol 370 mg I/mL. The study will focus on elderly subjects with either chronic renal insufficiency, or diabetes mellitus (DM) requiring drug therapy, or congestive heart failure (CHF) NYHA Class III or greater, who are referred for a coronary catheterization procedure with or without PCI.

Enrollment

284 patients

Sex

All

Ages

65+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Males and females 65 years of age with cardiovascular disease who are referred for a coronary catheterization procedure with or without PCI.
The subject has at least one of the following comorbidities:
1. Chronic renal insufficiency, (eGFR <60 but 15 mL/min/1.73 m2 according to the MDRD equation) as measured within 2 weeks or at the screening visit;
1. DM diagnosed greater than 6 months prior to study entry and which requires either insulin or anti-hyperglycemic drug therapy;
1. CHF (NYHA) class III or greater measured within 2 weeks of enrollment or at the screening visit.

Exclusion criteria

The subject has known allergies to either iodine or any ICM.
The subject has severe renal insufficiency (eGFR <15 mL/min/1.73 m2 according to the MDRD equation) or is on dialysis.
The subject has acute coronary syndrome requiring emergency coronary angiography and/or intervention.
The subject is not willing or unable to discontinue metformin (e.g., Glucophage) at the time of the study procedure.